Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 9/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093734 | 1.00 | CCR3 (0.45) | CCR3ROCK2ROCK1SLC1A2OPRD1 | |
| SCHEMBL13725003 | 0.83 | FAAH (0.43) | ROCK2ROCK1SLC1A2OPRD1 | |
| SCHEMBL13724803 | 0.83 | FAAH (0.43) | ROCK2ROCK1SLC1A2OPRD1 | |
| SCHEMBL4099505 | 0.81 | OPRL1 (0.47) | HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4099664 | 0.81 | OPRL1 (0.47) | HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13749435 | 0.79 | HRH3 (0.47) | HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13750181 | 0.79 | HRH3 (0.47) | HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4106900 | 0.76 | OPRM1 (0.50) | OPRD1HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4099473 | 0.76 | SLC6A4 (0.43) | HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4103236 | 0.76 | SLC6A4 (0.43) | HRH3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | CCR3 1211/4885ROCK2 4316/4885ROCK1 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.